CLMT: $347.2m of adjusted EBITDA fueled rapid deleveraging and a capital-light SAF expansion

Calumet, Inc. reported Q3 adjusted EBITDA of $347.2m, with leverage decreasing to 3.0x consolidated and 2.3x recourse. The company plans to expand its MaxSAF production to 200m gallons annually by the end of 2028, supported by debt reduction and specialty segment strength.

Original reporting
Published Nov 6, 2026, 12:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 7, 2026, 10:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CLMT: $347.2m of adjusted EBITDA fueled rapid deleveraging and a capital-light SAF expansion — source image
Decision brief

The 30-second read

$CLMTBullishMed
01

Why it matters

The earnings beat and deleveraging could attract value‑oriented investors.

02

Market read

First‑time disclosure of Q3 results provides fresh data for traders.

03

What to watch

Potential headwinds from raw material costs and future SAF demand uncertainty.

Relevance 7/10Novelty 8/10Timing: released today

Background

Calumet, Inc. released its Q3 financial summary, emphasizing adjusted EBITDA and leverage metrics.

Company-level read

Ticker impact

$CLMTBullishHigh confidence
Context

Q3 adjusted EBITDA of $347.2 million and leverage reduction to 3.0× were disclosed for the first time.

Expected impact

likely upward pressure as investors price in better cash flow and lower debt.

Evidence & confidence

The disclosed EBITDA and leverage improvement are material new data that can drive buying interest.

Market effects

Highlights strength in the specialty chemicals sector and may lift peers with similar business models.

Positive for U.S. mid‑cap industrial stocks.

Limited to investors tracking U.S. industrial earnings.

Counterpoint

If the market has already priced in the earnings beat, the stock may face a short‑term pullback.

Key entities

  • Calumet, Inc.

    U.S. specialty chemicals producer.

Related articles

$CLMTHighAI 8/10

Calumet (CLMT) Q3 2026 Earnings Call Transcript

Calumet (CLMT) reported Q3 2026 earnings with adjusted EBITDA of $347.2M, up from $92.5M in Q3 2025. Net income was $273.3M, down from $313.4M YoY. The company retired $265M in debt, reducing annual interest by $26M. Specialty Products and Solutions EBITDA was $248.1M, while Montana Renewables EBITDA was $110.6M. Management highlighted debt reduction, strategic restructuring, and plans to increase sustainable aviation fuel production.

$CLMTMed

What Calumet (CLMT) Said on Its Q3 Earnings Call

Calumet (CLMT) reported Q3 earnings, highlighting a completed turnaround at its Shreveport facility and progress on Montana Renewables' expansion. Adjusted EBITDA for Montana Renewables was $110.6M, with CMR contributing $40.8M. The company plans to increase sustainable aviation fuel production, with a path to 200M gallons annually by 2028. Debt reduction remains a priority, with $175M in 2028 notes outstanding.

$CLMTHighAI 8/10

Calumet Reports Third Quarter 2026 Results

Calumet, Inc. /DE (CLMT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Calumet Reports Third Quarter 2026 Results • Third Quarter 2026 net income of $273.3 million, or basic earnings per common share of $2.91 • Third Quarter 2026 Adjusted EBITDA with Tax Attributes of $347.2 million • Accelerated deleveraging continues with approximatel